Vigil Neuroscience is a biotechnology company focused on developing therapies that target microglia for neurodegenerative diseases. The company pursues novel drug candidates aimed at modulating microglial function in neurodegeneration. On June 28, 2024, Vigil announced a strategic investment from Sanofi totaling $40 million. Sanofi purchased shares at a price of $7.44 per share as part of the transaction. The announcement was reported by DoNews. The article does not disclose additional operating metrics, past financings, or other investors. Vigil Neuroscience is developing microglia-targeted medicines, including a fully human monoclonal antibody VGL101 and small-molecule agonists of TREM2, to treat rare and common neurodegenerative diseases. The company expects to initiate a Phase 1 study of VGL101 in healthy volunteers to evaluate safety, pharmacokinetics and pharmacodynamics by year-end 2021. Its first clinical indication is adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare CSF1R-mutant disease affecting an estimated 10,000 people in the U.S. with no approved therapies. Vigil plans a natural-history study enrolling ALSP patients to characterize disease features and evaluate fluid and imaging biomarkers. The small-molecule program is in lead optimization focused on potency, solubility, oral bioavailability and CNS uptake, with an aim to apply learnings to more common diseases such as Alzheimer’s Disease. The company completed a $90 million Series B to fund clinical and preclinical advancement of these programs. Vigil Neuroscience is focused on harnessing microglia to develop precision‑based therapies for rare and common neurodegenerative diseases. The company launched with late pre‑clinical assets in‑licensed from Amgen and is advancing multiple modalities, including a monoclonal antibody TREM2 agonist and a small‑molecule TREM2 agonist. Vigil plans to use its Series A financing to take the lead monoclonal antibody into Phase 1, advance the small‑molecule program to IND, and pursue additional assets to grow the pipeline. The company launched with $50 million in Series A financing and was co‑founded, seeded and incubated by Atlas Venture. Vigil is based in Cambridge, Mass. and is led by President and CEO Ivana Magovčević‑Liebisch. The stated goal is to build the evidence base supporting microglia biology as an important therapeutic pathway and deliver precision treatments to patients.

Total raised

$180M

Funding rounds

3

Latest round

Equity

Latest activity

Jun 2024